173. Development of a real time, interactive antimicrobial resistance dashboard
Session: Poster Abstract Session: Antimicrobial Stewardship: Current State and Future Opportunities
Thursday, October 8, 2015
Room: Poster Hall
Background:   Hospital-wide antibiotic resistance data are frequently used to make patient specific antimicrobial prescribing decisions. However, antibiograms are limited as there is often a delay in release of the compiled, annual results and the organisms tested are not linked to clinical data such as isolate source or clinical location at the time of culture. Additionally, methods for multiple hospitals to share real time bacterial resistance data are lacking. The objective of this study was to develop a hospital-wide, interactive, antimicrobial resistance dashboard.

Methods: We developed an automated analytics platform for the development of a pilot real time hospital-wide antimicrobial resistance dashboard limited to a single pediatric hospital. De-identified antibiotic resistance data were extracted from the microbiology lab and the electronic medical record from January 1, 2014 – December 31, 2014. Patient age, gender, 3 digit zip code of residence, specimen source, specimen site, isolate species, antibiotic tested with susceptibility result, clinical setting of where the culture was obtained (i.e. hospital, emergency department, clinic). Dates of specimen collection were grouped by week. The Clinical and Laboratory Standards Institute Guideline (M39-A4) was followed to determine inclusion criteria of bacterial isolates. The IRB deemed this non-human subjects research.

Results:  There were 7,499 culture isolates with 82,066 data points including method of susceptibility testing, antimicrobial dilution, interpretation, and week of testing. The interactive dashboard allowed for assessment of resistance patterns specific to bacterial species, antimicrobial resistance, isolate source and clinic location.

Conclusion: Development of an interactive antimicrobial resistance dashboard can successfully be constructed to provide more detailed and timely antimicrobial resistance data pertinent to specific clinical settings within a single institution. This information will be used by the antibiotic stewardship program to enhance decision making. The addition of other hospitals within the region will provide means for active antimicrobial surveillance trends within our community with the ability to merge and view data from multiple, non-affiliated institutions.

 

Jennifer Goldman, MD, MS1, Earl Glynn, MS2, Ronnie Blackburn, BA2, Jason Newland, MD, MEd, FPIDS3, Rangaraj Selvarangan, PhD4 and Mark Hoffman, PhD5, (1)Children's Mercy Hospitals & Clinics and University of Missouri-Kansas City, Kansas City, MO, (2)Center for Health Insights, University of Missouri – Kansas City, Kansas City, MO, (3)Children's Mercy Hospital and Clinics, Kansas City, MO, (4)Children's Mercy Hospital, Kansas City, MO, (5)Center for Health Insights, University of Missouri - Kansas Ctiy, Kansas City, MO

Disclosures:

J. Goldman, None

E. Glynn, None

R. Blackburn, None

J. Newland, Pfizer/Joint Commission: Grant Investigator , Research grant
RPSdiagnostics: Consultant , Consulting fee

R. Selvarangan, None

M. Hoffman, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.